AMENDMENTS

IN THE CLAIMS:

Please AMEND claims 1-7, 9-14, and 16-17 as follows:

1.   (Amended)   A method for prophylaxis or treating Sinusoidal Obstruction Syndrome comprising administering a matrix metalloproteinase inhibitor.

2.   (Amended)   A method for prophylaxis or treating chemotherapy- or radiation-induced liver disease comprising administering a matrix metalloproteinase inhibitor.

3.   (Amended)   The method of claim 2, wherein said chemotherapy-induced liver disease includes Sinusoidal Obstruction Syndrome, nodular regenerative hyperplasia, peliosis hepatis, immunosuppression-induced hepatic venoocclusive disease, and sinusoidal dilatation.

4.   (Amended)   The method of claims 1 or 2, wherein said matrix metalloproteinase inhibitor is doxycycline or 2-[(4-biphenylsulfonyl)amino]-3-phenyl-propionic acid.

5.   (Amended)   The method of claim 4, wherein said matrix metalloproteinase inhibitor is doxycycline.

6.   (Amended)   The method of claim 5 wherein 15 mg/kg of said doxycycline is administered twice daily.

7.   (Amended)   The method of claim 4, wherein said matrix metalloproteinase inhibitor is 2-[(4-biphenylsulfonyl)amino]-3-phenyl-propionic acid.

9.   (Amended)   The method of claims 1 or 2 wherein said matrix metalloproteinase inhibitor is administered for up to 4 weeks.

10.   (Amended)   The methods of claims 1 or 2 wherein said matrix metalloproteinase inhibitor is Marimastat, Prinomastat, (N-hydroxy-2(R)-[[4-methoxysulfonl](3-picolyl) amino]-3-methylbuteamide hydrochloride) monohydrate, Solimastat, (3(R)-(cyclopentylmethyl)-2(R)-[(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)methyl]-4-oxo-4-piperidinobutyrohydroxamic acid), Ilomastat, Metastat, Neovastat, or Periostat.

11.   (Amended)   A method for prophylaxis or treating chemotherapy or radiation induced liver disease comprising administering an effective dose of a matrix metalloproteinase inhibitor selected from doxycycline or 2-[(4-biphenylsulfonyl)amino]-3-phenyl-propionic acid.